56 results on '"Wils, J."'
Search Results
2. Nouveaux mécanismes de régulation de l’aldostérone
3. The practice of evidence based laboratory medicine among worldwide medical laboratory professionals: Competencies and need of training
4. Le système nerveux autonome stimule la sécrétion d’aldostérone par le biais de la substance P chez l’homme
5. CO-04: Aging altered epoxyeicosatrienoic acid-mediated regulation of peripheral conduit artery diameter at rest and during sustained flow-mediated dilatation
6. L’activation du système rénine-angiotensine intra-surrénalien est responsable d’un hyperaldostéronisme chez les souris déficientes en mastocyte en régime hyposodé
7. Implication de la sérotonine dans la physiopathologie de l’adénome de Conn
8. Dérégulations de la production d’aldostérone et de l’homéostasie hydrominérale dans un modèle murin déficient en mastocyte
9. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
10. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
11. Évaluation et rééducation
12. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
13. Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group
14. 302 Equal prognosis of elderly and non-elderly patients with metastatic colorectal cancer and 5-FU treatment: a retrospective analysis
15. 1088 Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986
16. 168 A phase II study of docetaxel, epirubicin, and cispiatin with G-CSF (ienograstim) support in patients with advanced ovarian cancer
17. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer
18. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
19. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
20. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients
21. Adjuvant treatment of colorectal cancer in the Netherlands: a commentary
22. Recent advances in the management of colorectal cancer
23. This letter was referred to the author, who responds as follows
24. Clinical determinants of tumor response in patients with 5-FU based treatment for metastatic colorectal cancer. Results of a multivariate analysis of 3825 patients
25. Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953
26. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives
27. Regional chemotherapy in the treatment of advanced pancreatic cancer — is it relevant?
28. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
29. Colorectal cancer
30. Gastric cancer
31. Gastrointestinal Tract Cancer Liaison Office: An attempt to organise clinical research in Europe
32. Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC GITCCG
33. The identification of high risk patients with metastatic colorectal cancer
34. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987)
35. Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?
36. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study
37. Letters to the editor
38. PP-7-6 Dose dense epirubicin (E) and paclitaxel (P) with G-CSF in metastatic breast cancer (MBC)
39. 546 Advanced gastric cancer: Comparison of FAMTX (5FU, adriamycine, methotrexate) versus elf (etroposide, 5 FU, leucovorin) versus FUP (infusional 5 FU+cisplatin). Results from an eortc trial of the GITCCG and the arbeitsgemeinschaft für innere onkologie (AIO)
40. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up
41. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer
42. Gastric Cancer: Current status and future directions in the treatment of localized gastric cancer
43. Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer
44. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients
45. Vinorelbine (Navelbine®) is an active drug in metastatic epidermoid esophageal carcinoma (MEEC)
46. Combined modality adjuvant treatment of high-risk rectal cancer: A treatment of choice or a choice of treatment?
47. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma
48. Adjuvant treatment of colon cancer: Where to go from here?
49. Phase II study of high-dose epirubicin in non-small cell lung cancer
50. An EORTC gastrointestinal group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.